BAFNA PHARMACEUTICALS LTD. - 532989 - Board Meeting Intimation for Board Meeting Intimation To Consider The Unaudited Results For The Half Year And Quarter Ended 30.09.2022
BAFNA PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/11/2022 ,inter alia, to consider and approve Board Meeting Intimation to consider the Unaudited Results for the Half year and Quarter ended 30.09.2022 BAFNA PHARMACEUTICALS LTD. - 532989 - Sale Of Equity Shares Of The Company By SRJR Life Science LLP Through Open Market Sale For Minimum Public Shareholding.
Sale of Equity Shares of the Company by SRJR Life Science LLP through open market sale for minimum public shareholding. BAFNA PHARMACEUTICALS LTD. - 532989 - Announcement under Regulation 30 (LODR)-Resignation of Company Secretary / Compliance Officer
With reference to the subject captioned above, we would like to inform you that Mrs. Roopa Ravikumar (Membership No:F11282) has resigned from the post of Company Secretary and Compliance officer of the Company with effect from closing hours of 11th August 2022. BAFNA PHARMACEUTICALS LTD. - 532989 - Board Meeting Outcome for .:- Regulation 30 Read With Reg. 33 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015
We would like to inform you that the Board at its meeting held today approved the unaudited financial results for the quarter ended 30th June 2022. Please find attached the unaudited financial results for the quarter ended 30th June 2022 along with the limited review report obtained from the statutory auditor of the Company. The Audit Committee of the Company has been reconstituted to include Ms. Chitra Ravichandran, Independent Director as member of the Committee. BAFNA PHARMACEUTICALS LTD. - 532989 - Board Meeting Intimation for Board Meeting To Consider The Unaudited Results For The Quarter Ended 30.06.2022
BAFNA PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/08/2022 ,inter alia, to consider and approve The unaudited results for the quarter ended 30.06.2022 BAFNA PHARMACEUTICALS LTD. - 532989 - Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
Attached is the scrutinizer report of the AGM held on 28.07.2022 BAFNA PHARMACEUTICALS LTD. - 532989 - Disclosure of Voting results of AGM (Regulation 44(3) of SEBI (LODR) Regulations, 2015)
Bafna Pharmaceuticals Ltd has informed BSE regarding the details of Voting results of AGM, under Regulation 44(3) of SEBI (LODR) Regulations, 2015. Kindly Click here BAFNA PHARMACEUTICALS LTD. - 532989 - Shareholder Meeting / Postal Ballot-Outcome of AGM
Please be informed that the 27th AGM of the Company was held on 28TH JULY 2022 through Video Conferencing ('VC')/ Other Audio Visual Means ('OAVM') at 11.00 a.m. IST. In this regard please find attached the summary of the proceedings of the AGM of the Company. The voting results of the 27th Annual General Meeting of the Company along with the Scrutinizer report will be shared shortly. The 27th Annual General Meeting of the Company was concluded at 11.30 A M We request you to take the above information on your record BAFNA PHARMACEUTICALS LTD. - 532989 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
We are enclosing herewith Certificate dated 4th July 2022 issued by Cameo Corporate Services Limited, Registrar and Transfer Agent (RTA) of the Company confirming the compliance of Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018. BAFNA PHARMACEUTICALS LTD. - 532989 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Pursuant to Regulation 30 read with Schedule III and Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed copies of newspaper advertisement published on 06th July 2022 in Business Standard (English) and Makkal kural (Tamil) regarding notice of the 27th Annual General Meeting ('AGM') of the Company for the Financial Year 2021 - 2022, to be held on Thursday, 28th July 2022 at 11: 00 am through video conferencing.